Latest news

• Merck's anti-PD1 drug promising in lung cancer

  MK-3475 was previously known as lambrolizumab but a new name is currently under review.

• AZ licenses Merck ovarian cancer drug

  For its part, Merck said the agreement would allow it to focus on its later-stage oncology projects, including the much-touted PD-1-targetting cancer immunotherapy lambrolizumab (MK-3475) and

• AZ adds to pipeline again with Amplimmune buy

  PD-1 is something of a hot target at the moment, with candidates such as Merck &Co's lambrolizumab and Bristol-Myers Squibb's nivolumab attracting a lot of attention thanks

• ASCO: Amgen says viral therapy for melanoma "encouraging"

  For T-VEC, interest is building around the concept of combining the virus with PD-1-targeting immunotherapies such as BMS' nivolumab and Merck &Co's lambrolizumab, which also generated new

• ASCO: Merck and BMS trumpet melanoma trials

  Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab. Merck &Co and Bristol-Myers Squibb (BMS) both presented positive phase III data for their anti-PD-1 melanoma candidates ... Merck presented data from a phase II study -